https://www.mayoclinic.org/tests-procedures/breast-biopsy/about/pac-20384812

Technical Classification and Core Working Mechanisms

Percutaneous breast needle biopsy is categorized into three mainstream technical modalities based on needle dimension, sampling mechanism and guidance approach: Fine-Needle Aspiration Biopsy (FNAB), Core Needle Biopsy (CNB), and Vacuum-Assisted Breast Biopsy (VAB). Each modality features distinctive physical principles, applicable clinical scenarios and diagnostic values.

Fine-Needle Aspiration Biopsy (FNAB) employs ultra-fine 21G–25G needles (0.5–0.8 mm outer diameter) to harvest cytological specimens via negative-pressure suction. Its core principle relies on vacuum generated by an attached syringe (typically 5–10 mL negative pressure), which draws loosely shed cellular material through the needle lumen into the syringe barrel. FNAB boasts straightforward manipulation, minimal tissue trauma, virtually scar-free healing and rapid preliminary diagnosis. However, as it retrieves isolated cells rather than intact tissue cores, diagnostic accuracy heavily hinges on operator proficiency and cytopathologist interpretation capability. FNAB cannot distinguish invasive carcinoma from in situ disease nor enable full immunohistochemical subtyping. In recent years, FNAB has demonstrated unique advantages for harvesting viable cells to establish Patient-Derived Organoids (PDOs): its gentle tissue dissociation preserves high cell viability and drastically shortens organoid culture cycles.

Core Needle Biopsy (CNB) stands as the most widely adopted histologic biopsy technique, commonly utilizing slotted 14G–18G cannulas (1.2–2.1 mm diameter) paired with spring-loaded automated biopsy devices. The biopsy gun mechanically propels the inner cutting stylet forward at high velocity (20–30 m/s), transecting and trapping intact tissue cores within the sampling notch. A standard 14G needle yields cylindrical tissue specimens measuring approximately 1–2 mm in diameter and 15–22 mm in length. Intact histologic architecture from CNB enables tumor grading, immunohistochemical biomarker testing (ER, PR, HER2, Ki-67) and molecular profiling, with overall diagnostic accuracy ranging from 95% to 98%. Its primary limitation is insufficient sampling of microcalcifications or non-mass lesions, carrying a roughly 2%–4% risk of pathological underdiagnosis.

Vacuum-Assisted Breast Biopsy (VAB) marks a landmark breakthrough in minimally invasive biopsy, utilizing 7G–12G rotary cutting probes (2.4–4.0 mm diameter). It operates on a dual-action mechanism combining rotary cutting and vacuum suction: first, high negative pressure (up to −25 inHg) pulls target tissue securely into the sampling trough; second, an inner cutter spinning at up to 1,500 RPM severs anchored tissue; lastly, resected specimens are automatically transported via vacuum tubing into an external collection container. A single skin puncture permits sequential multi-pass sampling, generating far larger tissue yields than CNB (over 100 mg per pass with a 7G probe), alongside reduced mechanical tissue injury and less than 5% cellular degeneration rate. Beyond diagnostic purposes, VAB achieves complete excision of benign lesions ≤3 cm such as fibroadenomas with an excision rate exceeding 90%.

Standardized Operating Procedures and Quality Control

Standardized procedural protocols underpin consistent biopsy success and reliable pathological diagnosis. A complete percutaneous breast biopsy workflow comprises three sequential phases: pre-procedural evaluation, intraprocedural manipulation and post-biopsy management.

Precise pre-procedural assessment and treatment planning lay the foundation for procedural success. All biopsy indications require rigorous correlation of clinical findings and multimodal imaging. Even palpable breast masses mandate pre-biopsy imaging (ultrasound, mammography or MRI) to characterize lesions and facilitate targeted puncture. Lesions are stratified per the Breast Imaging Reporting and Data System (BI-RADS); BI-RADS 4 (suspicious for malignancy) and above constitute formal biopsy indications. Clinicians select optimal guidance and biopsy techniques tailored to lesion features: ultrasound-guided sampling is first-line for solid sonographically visible masses; stereotactic X-ray guidance is reserved for mammography-only microcalcifications and architectural distortion; MRI-directed biopsy targets lesions exclusively identifiable on MRI. Preoperative preparation includes appropriate discontinuation of antiplatelet/anticoagulant agents (e.g., aspirin held for 3–5 days), written informed consent acquisition and peri-procedural psychological counseling for anxious patients.

Image-guided precise cannulation represents the procedural core. Ultrasound guidance dominates clinical practice for its real-time dynamic visualization, zero ionizing radiation and multiplanar scanning capability. Operators orient the transducer perpendicular to the skin and employ an in-plane puncture technique to maintain full sonographic visualization of the entire needle tract, restricting tip localization error below 0.5 mm. For stereotactic biopsy, patients lie prone on dedicated stereotactic tables with breast tissue suspended through an aperture and immobilized by compression paddles; a computer calculates three-dimensional lesion coordinates from dual-angle mammograms to navigate needle advancement. MRI-guided biopsy requires non-ferromagnetic biopsy instrumentation and MR-compatible accessories to localize targets on contrast-enhanced sequences. The coaxial trocar technique has gained widespread adoption across all modalities: a large-bore outer introducer sheath is positioned adjacent to the lesion margin first, allowing repeated core sampling through the sheath without repeated cutaneous puncture, thereby mitigating trauma, procedural pain and needle-track seeding risk.

Appropriate specimen handling and pathological handoff directly determine diagnostic reliability. Harvested tissue cores require immediate standardized processing. For routine histopathology, specimens are promptly immersed in sufficient 10% neutral buffered formalin at a minimum 1:10 tissue-to-fixative volume ratio with fixation duration ranging 6–72 hours to preserve tissue architecture for dependable immunohistochemistry. For calcification-targeted biopsy, specimen radiography is mandatory to confirm successful retrieval of microcalcifications; absent calcifications on radiography prompt repeat biopsy. All sampled tissue undergoes paraffin embedding and histologic sectioning; neither CNB nor VAB specimens are recommended for intraoperative frozen-section analysis, as freezing artifacts compromise permanent paraffin slide interpretation. Final pathological reports must correlate closely with preoperative imaging and clinical manifestations; substantial discordance between high-grade imaging suspicion and benign pathology mandates repeat core biopsy or excisional surgical biopsy for definitive diagnosis.

Cutting-Edge Technical Integration and Intelligent Innovation

Deep convergence of advanced imaging, robotic engineering and artificial intelligence is transforming breast biopsy from experience-dependent practice into data-driven precision medicine.

Multimodal image fusion and real-time navigation overcome limitations of standalone single-modality imaging. Preoperative high-resolution CT/MRI datasets are three-dimensionally co-registered with intraprocedural live ultrasound to reconstruct volumetric anatomical models of lesions alongside adjacent glands and vasculature. Ultrasound monitors display conventional two-dimensional grayscale images overlaid with fused CT/MRI reconstructions to deliver fluoroscopy-like transparent navigation. This technology is particularly valuable for challenging lesions adjacent to the chest wall, nipple or axilla, as well as isoechoic masses with poor sonographic delineation, lifting biopsy success rates for deep or anatomically complex lesions from 82% to 98%.

Robot-assisted biopsy systems represent the pinnacle of precision-guided intervention. Motorized manipulators eliminate inherent physiological hand tremor entirely. After clinicians outline virtual puncture trajectories at a master control console, robotic arms execute needle advancement with submillimeter accuracy down to 0.1 mm. Apart from improving first-pass targeting success, robotic systems enable systematic fan-shaped grid sampling across target lesions during multi-core VAB, minimizing sampling bias and missed pathology. Preclinical simulation data demonstrates 100% diagnostic specimen adequacy with robotic biopsy, compared to an 85% yield under conventional freehand operation.

Artificial intelligence and in vivo real-time tissue interrogation reshape clinical decision-making. Miniature fiber-optic needle endoscopes have been developed; probes sized equivalent to 34G acupuncture needles (0.15 mm diameter) integrate triple-modal White-light, Autofluorescence and Raman (WAR) spectroscopy. The system instantaneously analyzes in situ biochemical composition along the advancing needle path and applies machine learning to differentiate benign from malignant tissue in real time. Though still in preclinical development, this innovation is poised to shift traditional "sample-transport-wait" biopsy toward an integrated "puncture-and-immediate-diagnosis" paradigm to reduce unnecessary invasive sampling.

Theranostic-integrated probes expand the functional scope of biopsy devices. Novel electrosurgical biopsy needles combine high-frequency electrosurgical cutting with vacuum-assisted harvesting; concurrent electrocoagulation seals microvessels during tissue resection to reduce intraprocedural hemorrhage and postoperative hematoma formation. Forward-looking designs incorporate built-in drug delivery lumens within biopsy cannulas: upon completion of diagnostic sampling, chemotherapeutics or immunotherapies can be injected directly into the lesion through the identical needle tract to realize same-session diagnosis and targeted treatment. Radiofrequency-enabled biopsy marker clips are also widely utilized: after specimen retrieval, radiopaque metallic markers are deployed into biopsy cavities under image guidance to facilitate precise intraoperative localization should subsequent surgical excision be required.

From a standalone diagnostic test, percutaneous breast needle biopsy has evolved into an integrated theranostic platform uniting precision mechanical engineering, advanced radiology, molecular pathology and artificial intelligence. Its developmental mission remains consistent: to deliver robust evidence for precise breast disease diagnosis and personalized therapy with minimal invasiveness, superior accuracy and expedited procedural workflow.